JACC Heart Failure:房颤与血浆利钠肽水平升高相关

2013-06-08 高晓方 译 医学论坛网

  在无心衰的情况下,房颤与血浆利钠肽(MR-proANP、BNP和NT-proBNP)水平升高具有相关性。论文于6月3日发表于《美国心脏病学会杂志:心衰》(JACC:Heart Failure)。   此项研究共纳入1445例急性呼吸困难患者。在无房颤且无心衰患者中三种利钠肽血浆浓度最低。在无心衰的房颤患者中三种利钠肽的血浆浓度显著升高,在伴和未伴房颤的心衰患者中则进一步升高(P&n

心脏好图

  在无心衰的情况下,房颤与血浆利钠肽(MR-proANP、BNP和NT-proBNP)水平升高具有相关性。论文于6月3日发表于《美国心脏病学会杂志:心衰》(JACC:Heart Failure)。

  此项研究共纳入1445例急性呼吸困难患者。在无房颤且无心衰患者中三种利钠肽血浆浓度最低。在无心衰的房颤患者中三种利钠肽的血浆浓度显著升高,在伴和未伴房颤的心衰患者中则进一步升高(P 均<0.001)。无房颤时三种利钠肽均可有效鉴别心衰,伴房颤时MR-proANP、BNP和NT-proBNP的诊断效能则明确降低。上述结果提示房颤存在时需考虑利钠肽的不同诊断阈值。

  专家评论指出,此项研究结果在急性心衰患者生物标志物数据临床解读,以及利用利钠肽指标作为纳入标准的临床试验设计方面均具有重要意义。新型心衰生物标志物应主要反映心衰病理生理学所涉及的重要通路,而不应是利钠肽等已有临床信息的重复。

Atrial Fibrillation Impairs the Diagnostic Performance of Cardiac Natriuretic Peptides in Dyspneic Patients:
Results From the BACH Study (Biomarkers in ACute Heart Failure)
Objectives 
The purpose of this study was to assess the impact of atrial fibrillation (AF) on the performance of mid-region amino terminal pro-atrial natriuretic peptide (MR-proANP) in comparison with the B-type peptides (BNP and NT-proBNP) for diagnosis of acute heart failure (HF) in dyspneic patients.
Background 
The effects of AF on the diagnostic and prognostic performance of MR-proANP in comparison with the B type natriuretic peptides have not been previously reported.
Methods 
A total of 1,445 patients attending the emergency department with acute dyspnea had measurements taken of MR-proANP, BNP, and NT-proBNP values on enrollment to the BACH trial and were grouped according to presence or absence of AF and HF.
Results 
AF was present in 242 patients. Plasma concentrations of all three peptides were lowest in those with neither AF nor HF and AF without HF was associated with markedly increased levels (p < 0.00001). HF with or without AF was associated with a significant further increment (p < 0.00001 for all three markers). Areas under receiver operator characteristic curves (AUCs) for discrimination of acute HF were similar and powerful for all peptides without AF (0.893 to 0.912; all p < 0.001) with substantial and similar reductions (0.701 to 0.757) in the presence of AF. All 3 peptides were independently prognostic but there was no interaction between any peptide and AF for prediction of all-cause mortality.
Conclusions 
AF is associated with increased plasma natriuretic peptide (MR-proANP, BNP and NT-proBNP) levels in the absence of HF. The diagnostic performance of all three peptides is impaired by AF. This warrants consideration of adjusted peptide thresholds for diagnostic use in AF and mandates the continued search for markers free of confounding by AF.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906183, encodeId=1f5b19061830d, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Jan 27 16:49:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853233, encodeId=377118532338b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 21 09:49:00 CST 2013, time=2013-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324825, encodeId=dd6613248250d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355767, encodeId=7eff1355e674f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366463, encodeId=995c13664630f, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562165, encodeId=1ad615621652e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
    2014-01-27 amy0550
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906183, encodeId=1f5b19061830d, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Jan 27 16:49:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853233, encodeId=377118532338b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 21 09:49:00 CST 2013, time=2013-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324825, encodeId=dd6613248250d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355767, encodeId=7eff1355e674f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366463, encodeId=995c13664630f, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562165, encodeId=1ad615621652e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
    2013-06-21 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1906183, encodeId=1f5b19061830d, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Jan 27 16:49:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853233, encodeId=377118532338b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 21 09:49:00 CST 2013, time=2013-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324825, encodeId=dd6613248250d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355767, encodeId=7eff1355e674f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366463, encodeId=995c13664630f, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562165, encodeId=1ad615621652e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906183, encodeId=1f5b19061830d, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Jan 27 16:49:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853233, encodeId=377118532338b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 21 09:49:00 CST 2013, time=2013-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324825, encodeId=dd6613248250d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355767, encodeId=7eff1355e674f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366463, encodeId=995c13664630f, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562165, encodeId=1ad615621652e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
    2013-06-10 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1906183, encodeId=1f5b19061830d, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Jan 27 16:49:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853233, encodeId=377118532338b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 21 09:49:00 CST 2013, time=2013-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324825, encodeId=dd6613248250d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355767, encodeId=7eff1355e674f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366463, encodeId=995c13664630f, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562165, encodeId=1ad615621652e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1906183, encodeId=1f5b19061830d, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Jan 27 16:49:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853233, encodeId=377118532338b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 21 09:49:00 CST 2013, time=2013-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324825, encodeId=dd6613248250d, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355767, encodeId=7eff1355e674f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366463, encodeId=995c13664630f, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562165, encodeId=1ad615621652e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Jun 10 01:49:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
    2013-06-10 slcumt

相关资讯

杨水祥 岳语喃:CFAE消融治疗房颤的全新策略

摘要:     肺静脉隔离(PVI)是导管消融治疗心房颤动(AF)的主要方法。消融靶点为复杂心房碎裂电位(CFAE)的消融方法不仅AF终止率较高,而且在没有肺静脉隔离(PVI)的阵发AF或者持续AF中都取得了良好的效果。本文将讨论CFAE指导下的独立消融或结合肺静脉隔离的房颤消融如何在临床上制定合理有效的消融策略。 1.前言     确定

Europace:存在危险因素的无症状性房颤的发生率

房颤是临床上最常见的持续性心律失常,其在普通人群中的发病率至少为1%,在大于40岁的人群中,每4人中就有1人至少经历过1次房颤发作。随着西方国家老龄化的进程,预计在30年后房颤患者将增加2倍甚至3倍。许多房颤患者无明显症状,因此不能得到诊断,许多房颤都是在出现脑卒中、心衰等并发症后才被诊断。房颤的主要并发症是脑卒中,可严重影响患者的预后和生活质量,口服抗凝药物可预防2/3的脑卒中发生,一些研究发现

Eur Heart J:临床研究发现服用地高辛患者的死亡率增加

地高辛广泛用于房颤的控制。然而,地高辛与死亡率增加有关。是否地高辛本身的毒副作用还是用药者体质弱并且有合并症导致死亡率增加,尚不清楚。近期,美国的吉尔心脏研究所肯塔基大学的一项研究表明地高辛与房颤病人的死亡率增加密切相关,该结果发表在《欧洲心脏杂志》上。 该研究应用多元Cox比例风险模型评估了节律管理会随访调查的房颤病人死亡率与地高辛的关系。研究分析了心衰患者或非心衰患者及所有亚群,心衰定义为有

HRS2013:CABANA试验4年内不会完成 可能产生阳性结果

  2013年5月8~11日美国心律学会(HRS)第34届年会在美丽的海拔“一英里高”城市丹佛盛大召开。会上公布了多项心律失常领域最新临床试验结果,来自世界各地的学者们在大会“科学、发现、创新——纪念过去,塑造未来”的主题下交流讨论,碰撞思想火花。   本报特邀亲临现场的国内专家带来此次盛会的最新热点内容,以飨读者。   众人瞩目的CABANA试验4年内不会完成   研究者预测可能产生阳性结

Int J Cardiol:牙周治疗降低房颤风险

牙周治疗带来的口腔卫生改善与心血管事件风险降低有关。由此,台北荣民总院林幸荣和江晨恩等人研究了牙周治疗与房颤(AF)的关系。结果显示,牙周治疗可以降低房颤风险,研究在2013年2月27日发表于《国际心脏病学杂志》。2000年,研究人员从台湾“全民健康保险研究资料库”中挑选出28,909名年龄不低于60周岁的受试者,所有受试者均无心律失常病史。其中连续三年(1998-2000)至少每年接受1次牙周治

Europace:成功的导管消融可减少CHA2DS2-VASc评分≥1分房颤患者的心血管事件发生

房颤是临床常见的心律失常,是脑卒中发生的独立预测因子。近年来导管消融被认为是有症状者或药物治疗无效的房颤患者的有效治疗手段,然而目前大多数临床研究的随访时间均较短,且入选的患者多属低危,因此目前对于房颤患者成功导管消融能否改善患者的长期预后还不清楚。 目前的理论认为无症状的房颤患者较使用抗心律失常药物的患者具有更好的临床预后,因此我们认为导管消融后无房性心律失常发作可显着改善患者的临床症状,因此